INTRODUCTION
Epidermal growth factor receptor (EGFR) is a validated oncogene, prognostic biomarker, and therapeutic target in head and neck squamous cell carcinoma (HNSCC). Cetuximab, a monoclonal antibody that competitively inhibits EGFR at its extracellular binding domain, improves locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) when combined with radiation therapy (RT) in patients with locally advanced HNSCC. 1, 2 Combined cetuximab and RT (cetuximab-RT) is an established standard for locally advanced HNSCC 3 and is the predominant therapeutic strategy in the United States and Europe for patients who are elderly, frail, or unfit for cisplatin. 4, 5 Because locoregional failure remains the major cause of death after cisplatin-based or cetuximab-based RT, 1, 6 treatments to enhance LRC remain a major unmet clinical need.
Cancer October 1, 2018 Despite the near-universal expression of EGFR in HNSCC, cetuximab benefits only a minority of patients. 1, 7, 8 In the recurrent/metastatic setting, the response rate (RR) for cetuximab is from 10% to 13%, 8 suggesting a rapid escape from extracellular inhibition. The EGFR-antisense plasmid DNA pNGVL1-U6-EG-FRAS (hereinafter referred to as EGFR-AS) is a 39-basepair DNA plasmid that spans the translation start site for the EGFR gene and was designed to generate high expression of intracellular EGFR-antisense messenger RNA. We previously demonstrated that EGFR-AS decreased cellular proliferation compared with EGFR-sense control plasmid in well characterized HNSCC cell lines, and this decrease was mediated by decreased translation of EGFR and the sustained down-modulation of EGFR protein expression. 9, 10 In vivo, intratumoral injection of EGFR-AS, but not EGFR-sense, inhibited tumor growth, coincident with increased apoptosis and suppressed EGFR protein expression in HNSCC xenografts. 11 We previously reported a phase 1 study evaluating intratumoral injection of EGFR-AS in patients with recurrent/metastatic HNSCC. 12 In that study, EGFR-AS caused no dose-limiting toxicities (DLTs) and yielded a promising lesional RR of 29%. This tolerability and efficacy profile raises the possibility that EGFR-AS injections could augment LRC if added to definitive cetuximab-RT.
We hypothesized that a dual anti-EGFR strategy of intratumoral EGFR-AS injections to reduce EGFR expression levels and systemic cetuximab to inhibit residual, extant EGFR may increase antitumor efficacy. We evaluated this combination in preclinical HNSCC models to characterize the mechanism and antitumor effects.
We also evaluated the combination of EGFR-AS injections, cetuximab, and RT in a phase 1 cohort of patients with locally advanced HNSCC.
MATERIALS AND METHODS

Preclinical Methods
HNSCC cell lines and reagents, viability and immunoblotting assays, xenograft models, and statistical methods are described in Supporting Figure 1 .
Clinical Trial Methods
Eligibility
The phase 1 trial was approved by the Institutional Review Boards of the University of Pittsburgh and the University of Texas San Antonio; both sites were nationally registered at clinicaltrials.gov (NCT00903461 and NCT01592721). All patients provided written, informed consent.
Key eligibility criteria included: stage IVA through IVC, histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx, as defined by the American Joint Committee on Cancer Staging Handbook, seventh edition; the presence of a primary tumor or lymph node that was measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 13 and accessible for repeated injections and mandatory research biopsies; and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Radiation-naive patients who had stage IVC disease with asymptomatic distant metastases were eligible if local control was judged clinically necessary by the investigator; however, head and neck reirradiation was not permitted. Cancer October 1, 2018
Treatment plan
The treatment schema is presented in Figure 1 . Given the negligible toxicity of EGFR-AS injections at any dose during the phase 1 monotherapy trial, 12 the highest dose of 1.92 mg/1.92 mL was selected for development in combination with cetuximab and RT. Treatment duration was 9 weeks. Cetuximab was administered as a loading dose of 400 mg/m 2 intravenously during week 1 followed by 250 mg/m 2 per week during weeks 2 through 9. Starting at week 1, EGFR-AS was injected weekly into the selected lesion for 7 weeks or until patients attained a complete response (CR). Patients underwent computed tomography-based treatment planning with intensitymodulated RT. The total radiation dose to gross disease was from 70 to 74 grays administered at 2 grays per fraction over 7 weeks starting at week 3. All locoregional disease was incorporated within the radiation field; distant metastases, if present, were not treated with radiation therapy.
Manufacture of investigational product
Clinical grade pNGVL1-U6-EGFRAS (EGFR-AS) was produced under good manufacturing practice conditions at the Center for Biomedicine and Genetics at the City of Hope (Duarte, Calif) to the City of Hope's Master File BB-MF-9778, as previously described. 12 Funding for drug manufacture was provided by the National Institute of Health's National Gene Vector Laboratory (NGVL) program.
Research biopsies
Pretreatment and posttreatment tumor specimens were obtained from the injected lesion at the time of diagnostic evaluation and after 2 doses of EGFR-AS and cetuximab, before the initiation of RT. A representative portion of each tumor was snap frozen. A reverse-phase protein array was performed on lysates from snap-frozen specimens, as previously described.
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Statistical Methods
This phase 1 trial was designed to enroll 11 patients to a fixed-dose combination of intratumoral EGFR-AS, cetuximab, and RT. Because no grade 2 or higher adverse event (AE) was observed during phase 1 development of intratumoral EGFR-AS, the highest previously tested dose of EGFR-AS was implemented without a plan for further escalation. The primary objective was to evaluate safety. The primary endpoint was DLT, defined as any grade 3 or 4 AE according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0 at least possibly related to EGFR-AS. The design sought to rule out an unacceptable DLT rate ≥20%. If no grade 3 or 4 AEs caused by EGFR-AS were observed, then the upper 90% confidence bound for the DLT rate would be <20%. Locoregional RECIST responses were categorized by computed tomography scans obtained 8 to 12 weeks after the completion of RT. 13 To qualify for a lesional CR, complete disappearance of the injected lesion was required. To qualify for a locoregional CR, complete disappearance of all locoregional disease within the radiated head and neck field was required. In patients with stage IVC disease, distant metastases were not included as target lesions when assessing lesional and locoregional response.
RESULTS
Dual EGFR Inhibition With Cetuximab and EGFR-AS Reduces Cell Viability
Both cetuximab and EGFR-AS reduce HNSCC proliferation and viability as monotherapy 15 ; however, the combination has not been evaluated in preclinical models. We determined the proportion of HNSCC 15B cells that survived treatment with vehicle control, cetuximab, EGFR-AS, or the combination. The combination significantly reduced viability compared with either agent alone (P < .0001), as indicated in Figure 2A .
The Combination of Cetuximab and EGFR-AS Enhances Antitumor Effects in Vivo
We previously demonstrated that EGFR-AS was as effective as cetuximab alone in reducing tumor growth in a 1483 xenograft model, whereas EGFR-sense treatment was not, indicating a sequence-specific treatment effect rather than a nonspecific effect of plasmid treatment. 16 After establishing that dual EGFR targeting with cetuximab and EGFR-AS reduced HNSCC cell line viability, we evaluated the combination in a 4-arm in vivo experiment. Two groups of 10 mice were inoculated in the flank bilaterally with 1483 cells, then randomized to intraperitoneal vehicle versus cetuximab. To control for animal heterogeneity in the comparison of EGFR-AS with EGFR-sense, each mouse served as its own control. EGFR-AS was injected into the left flank tumor, and EGFR-sense was injected into the right flank tumor. Thus, this was a 4-treatment experiment evaluating xenograft growth when treated with vehicle plus intratumoral EGFR-AS, vehicle plus EGFR-sense, cetuximab plus EGFR-AS, and cetuximab plus EGFR-sense. Cetuximab plus EGFR-sense decreased the rate of tumor growth relative to vehicle plus EGFR-sense (P = .0009), as illustrated in Figure 2B . However, the growth rate of tumors treated with the combination of cetuximab and intratumoral EGFR-AS was significantly lower than that of tumors treated with the combination of cetuximab and intratumoral EGFR-sense in the contralateral flank of the same mouse (P = .0003). The antitumor effects of cetuximab and EGFR-AS were additive (P interaction = .35). Collectively, these findings suggest that the antitumor activity of the combination of cetuximab plus EGFR-AS depends on both the systemic effects of cetuximab and the antisense construct.
Total EGFR Expression Is Decreased in Tumors Treated With Cetuximab and EGFR-AS
The combination of cetuximab plus EGFR-sense plasmid DNA reduced tumor size relative to vehicle plus EGFRsense in the 1483 HNSCC xenograft model, confirming that cetuximab has antitumor effects in this model. The combination of cetuximab plus EGFR-AS was significantly more effective than cetuximab plus EGFR-sense, indicating specificity of the antisense construct. To elucidate a possible mechanism, we evaluated paired, posttreatment tumor specimens from 4 mice treated with cetuximab plus intratumoral injection of both EGFR-AS (left flank) and EGFR-sense (right flank). Higher EGFR levels were observed in tumors treated with intratumoral EGFR-sense (Fig. 2C) , suggesting that the combination of cetuximab plus EGFR-AS resulted in EGFR protein down-modulation.
Preliminary Safety of EGFR-AS, Cetuximab, and RT
Because of the safety profile of EGFR-AS during phase 1 development, the lesional RR, and preclinical evidence suggesting enhanced antitumor activity from combined cetuximab and EGFR-AS, we initiated a phase 1 trial evaluating the safety of intratumoral EGFR-AS, cetuximab, and intensity-modulated RT in patients with stage IVA through IVC HNSCC. Six patients were enrolled at the University of Pittsburgh and the University of Texas San Antonio from May 2013 to April 2014, when the trial closed prematurely because of exhaustion of the EGFR-AS supply. EGFR-AS had been produced under the NGVL program, which was subsequently terminated. 17 Patient characteristics are presented in Table 1 . The Consolidated Standards for Reporting Trials (CONSORT) diagram for the 6 treated patients is presented in Figure 1B . The lesional RR for injected lesions was 83% (5 of 6 patients; 4 CRs and 1 partial response [PR]; 90% confidence interval, 56%-100%). The overall locoregional RR was 83% (5 of 6 patients; 3 CRs and 2 PRs).
Regimen-related toxicities are presented in Table 2 . Acneiform rash and radiation dermatitis were consistent with toxicity patterns for cetuximab-RT. 1 The DLT rate was 0% (0 of 6 patients; 90% confidence interval, 0%-31%). No grade 2 or higher AEs were attributed to Cancer October 1, 2018
EGFR-AS injections, in line with the phase 1 monotherapy experience. The protocol as designed required 11 accrued patients and a 0% DLT rate to conclude that the true DLT rate was <20%. Because we were unable to meet the accrual objective, we cannot make this claim. However, the absence of unacceptable AEs among 6 patients provides 90% confidence that the DLT rate is ≤31%.
Discordant CR of Large, Injected Neck Lesion
The locoregional RECIST response category for each patient was identical to the lesional response category, with 1 notable exception. Patient 5 initially presented in 2011 with stage IVC hypopharyngeal disease, including bilateral cervical adenopathy and pathologically confirmed pulmonary metastases. After an initial CR to frontline, systemic therapy (which included cisplatin, 5-fluorouracil, and cetuximab), he relapsed only within the hypopharynx and bilateral neck while remaining without radiologic evidence of pulmonary metastases. Because he had symptomatic locoregional disease, quiescent distant metastases, and no prior radiation therapy, he was deemed eligible and enrolled in the current trial. According to the protocol, all patients with locoregional disease received definitive cetuximab-RT. A hypermetabolic, 5-cm, left, level II/III lymph node was selected for injection of EGFR-AS, and 2 contralateral hypermetabolic lymph nodes were not injected (Fig. 3) . After he completed protocol treatment, the patient demonstrated an anatomic and metabolic CR of the injected lesion, but In models of head and neck squamous cell carcinoma, cetuximab with epidermal growth factor receptor-antisense plasmid DNA enhance antitumor effects. In a phase 1 cohort, the combination of intratumoral epidermal growth factor receptor-antisense DNA, cetuximab, and radiation therapy is well tolerated.
a No dose-limiting toxicities were attributed to epidermal growth factor receptor-antisense plasmid DNA injections, although epidermal growth factor receptor-antisense plasmid DNA was associated with grade 1 injection site discomfort in 2 patients. Observed rates of rash, mucositis, and RT dermatitis were consistent with the rates for cetuximab-RT. Cancer October 1, 2018 only an anatomic and metabolic PR of the contralateral noninjected lymph nodes. A consolidative right neck dissection confirmed the presence of viable residual disease. Ultimately, the patient died from complications of right neck disease 3 years after completing protocol therapy, but he never relapsed within the left neck. The patient essentially served as his own control; the discordant and sustained CR in the larger injected lesion suggests that EGFR-AS contributed to immediate and long-term lesional control.
Total EGFR Expression in Paired Tumor Biopsies
Biopsies were obtained at baseline and after 2 weeks of protocol treatment in all 6 patients. Four of 6 biopsies (67%) provided sufficient tissue for paired proteomic analysis using a reverse-phase protein array. Because of the small sample size, we limited our descriptive analysis to total EGFR expression, for which the greatest body of mechanistic preclinical data exists, and no significance testing was performed. Total EGFR expression decreased numerically in these 4 patients, ranging from 1.2 to 2.3 at baseline and from 0.9 to 1.8 (17%-52% decrease) at week 2.
CONCLUSIONS
After attaining regulatory approval from the US Federal Drug Administration and the European Medicines Association's for cetuximab in 2006, the combination of cetuximab and definitive RT rapidly became an accepted standard for locally advanced HNSCC in both North America and Europe. 1, 18, 19 However, among patients who receive treatment with cetuximab-RT, the median LRC is only 24 months, and the major cause of cancer mortality remains locoregional failure. 1, 18 We hypothesize that EGFR-AS injections may improve LRC without added toxicity. In the current study, we present preclinical evidence that combined extracellular EGFR blockade with cetuximab and transcriptional EGFR down-regulation with intratumoral EGFR-AS enhances antitumor activity and is associated with decreased tumor EGFR protein levels. Furthermore, we report the preliminary safety of intratumoral EGFR-AS, cetuximab, and RT in a phase 1 cohort.
This treatment strategy may be particularly relevant in elderly patients (defined as age ≥65 years), who represent >40% of incident HNSCCs, suffer more than one-half of HNSCC-related mortality, and predominantly receive treatment with cetuximab-RT. 5, 20 In a US analysis for the period from 2001 to 2009, the use of combined-modality therapy in the elderly population doubled from 29% to 61%-a rise attributable to the adoption of cetuximab-RT. 5 This striking change in clinical practice likely reflects the favorable systemic toxicity profile. Although cetuximab increases in-field mucosal and dermatologic toxicity, systemic toxicities (including the hematologic, renal, and gastrointestinal AEs discordantly observed in elderly patients who receive cisplatin) are rare. 21, 22 Although EGFR is an established oncogene and prognostic biomarker in HNSCC, no molecular biomarkers have been identified that can predict clinical benefit from cetuximab, including EGFR, RAS, or RAF mutations; EGFR protein expression; or EGFR amplification. 2, [23] [24] [25] Indeed, cetuximab and EGFR receptor tyrosine kinase inhibitors are near-universally active in well characterized HNSCC cell lines, representing an Achilles heel for clinical translation. 26, 27 We previously demonstrated that EGFR-AS decreased EGFR messenger RNA transcripts and EGFR protein levels in HNSCC cells, a mechanism distinct from cetuximab or EGFR receptor tyrosine kinases. [9] [10] [11] Transcriptional deregulation of EGFR also may be mechanistically important in humans, because downregulation of EGFR expression was observed in pretreatment and posttreatment tumor biopsies during phase 1 development of intratumoral EGFR-AS. 12 Moreover, baseline overexpression of EGFR was associated with lesional response, suggesting that EGFR protein expression ultimately may be a relevant biomarker for EGFR-AS, also distinct from EGFR inhibitors currently in the clinic. The data from the current studies expand on these earlier findings. Specifically, intratumoral EGFR-AS reduced HNSCC xenograft size relative to control EGFR-sense in mice treated with systemic cetuximab, and this difference was associated with the down modulation of EGFR expression. In the current phase 1 cohort, EGFR expression was reduced by 17% to 52% during the 2-week window of dual EGFR-AS and cetuximab therapy, although mechanistic conclusions are inhibited because of the small sample size. Although the findings are anecdotal, 1 patient demonstrated a discordant, sustained, metabolic and anatomic CR in a 5-cm, injected lymph node compared with a 1.5-cm, noninjected lymph node, suggesting that intratumoral EGFR-AS contributed to acute and long-term lesional control from cetuximab-RT.
The chief limitation of this phase 1 study was the inability to complete accrual to the 11-patient safety cohort because of exhaustion of the initial EGFR-AS drug supply and subsequent defunding of the NGVL.
Cancer October 1, 2018 The National Center for Research Resources inaugurated the NGVL in 2005 to encourage the manufacture of high-quality, clinical-grade vectors for gene-therapy trials. Major setbacks in the gene therapy treatment of ornithine transcarbamylase deficiency and X-linked severe combined immunodeficiency resulted in a severe contraction of gene therapy initiatives by the National Institutes of Health. 17 As systematic safety and monitoring measures are implemented for gene therapy clinical trials, and new clinical breakthroughs involving gene therapy are documented, there is resurgence in public and private investment in promising molecules. Rekindled development of EGFR-AS, recently licensed by Benetec Biopharma (Sydney, New South Wales, Australia), may be of clinical interest locally advanced HNSCC.
In summary, the morbidity and mortality associated with locoregional failure after cetuximab-RT in patients with locally advanced HNSCC should motivate therapeutic innovations to enhance LRC. EGFR-AS is a novel DNA plasmid that appears to transcriptionally deregulate EGFR, resulting in the down-modulation of EGFR protein expression. At least in part, this unique mechanism may underlie the enhanced antitumor activity of the combination of cetuximab and EGFR-AS observed in vivo and may contribute to the clinical activity of EGFR-AS. The combination of intratumoral EGFR-AS, cetuximab, and intensity-modulated RT was well tolerated and associated with promising local control in 6 patients. Therefore, this treatment strategy may be particularly relevant in elderly patients, for whom cetuximab-RT is the dominant therapeutic paradigm. To date, the safety of the combination of EGFR-AS, cetuximab, and RT and the identification of the patient population most likely to benefit remain unanswered questions. An expanded cohort or a de novo phase 2 trial will be required to fully evaluate safety and establish efficacy, with the primary endpoint of LRC.
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